Sun Qiang, Wang Anqi, Chang Hong
Department of Ultrasound, Qishan Hospital Yantai 264000, Shandong, P. R. China.
Department of Ultrasound, Yantai Zhifu Hospital Yantai 264000, Shandong, P. R. China.
Am J Transl Res. 2023 Jun 15;15(6):3856-3863. eCollection 2023.
To investigate the efficacy of contrast-enhanced ultrasound (CEUS)-guided radiofrequency ablation (RFA) in the treatment of liver cancer and its effect on patients' immune function.
Clinical data of 84 liver cancer patients admitted to the Shandong Qishan Hospital from March 2018 to March 2020 were retrospectively analyzed. According to differences in treatment methods, patients were divided into a research group (42 cases treated by CEUS-guided RFA) and a control group (42 cases treated by RFA under conventional ultrasound). Clinical efficacy of two groups was observed two months after surgery. Liver function as well as IgA, IgG and IgM levels were evaluated. The incidence of complications, quality of life and survival were compared between the two groups.
The complete inactivation rate of large lesions in the research group was 23.81%, which was significantly higher than that of the control group (4.76%). Before treatment, the two groups showed similar levels of IgA, IgG and IgM. After treatment, significantly increased levels were observed in both groups, but the research group had higher IgA, IgG and IgM levels as compared to the control group (P < 0.05). The quality of life scores increased in both groups after the intervention, and the score in the research group was significantly higher than that in the control group (P < 0.05). The progression-free survival of patients in the research group (12.28±5.42) was longer than that of patients in the control group (8.50±4.47; P < 0.05).
Comparing to RFA guided by conventional ultrasound, RFA guided by CEUS can reduce liver damage, lower the incidence of complications, enhance the body's immune system, and improve local control rate and progression-free survival time in patients with liver cancer.
探讨超声造影（CEUS）引导下射频消融（RFA）治疗肝癌的疗效及其对患者免疫功能的影响。
回顾性分析2018年3月至2020年3月在山东岐山医院收治的84例肝癌患者的临床资料。根据治疗方法的不同，将患者分为研究组（42例接受CEUS引导下RFA治疗）和对照组（42例接受常规超声引导下RFA治疗）。术后两个月观察两组的临床疗效。评估肝功能以及IgA、IgG和IgM水平。比较两组并发症的发生率、生活质量和生存率。
研究组大病灶的完全灭活率为23.81%，显著高于对照组（4.76%）。治疗前，两组的IgA、IgG和IgM水平相似。治疗后，两组水平均显著升高，但研究组的IgA、IgG和IgM水平高于对照组（P<0.05）。干预后两组的生活质量评分均升高，且研究组的评分显著高于对照组（P<0.05）。研究组患者的无进展生存期（12.28±5.42）长于对照组（8.50±4.47；P<0.05）。
与常规超声引导下的RFA相比，CEUS引导下的RFA可减少肝损伤，降低并发症发生率，增强机体免疫系统，并提高肝癌患者的局部控制率和无进展生存期。
